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Book Review
Review of Robert Whitaker, Anatomy of
an Epidemic: Magic Bullets, Psychiatric
Drugs, and the Astonishing Rise of
Mental Illness in America5
Reviewed by Martha J. Farah, University of Pennsylvania
Books exposing the misdeeds of the pharmaceutical indus-
Q1
try are so common these days that pharma–bashing has
become a genre unto itself. Especially in the realm of psy-10
chopharmacology, the pharmaceutical industry has given
us plenty of grist for shocking exposes and scathing cri-
tiques. I call attention to this body of literature in order to
say: Do not assume that Robert Whitaker’s book, Anatomy
of an Epidemic: Magic Bullets, Psychiatric Drugs, and the As-15
tonishing Rise of Mental Illness in America, is just another
anti–psychopharm diatribe.
Granted, Whitaker is no fan of the pharmaceutical in-
dustry. But his book is an attempt tomake avery specific and
novel point about current psychiatric treatments, a point20
that can be stated entirely independently of the politics of
big pharma and psychiatry. Whitaker’s thesis is that mental
illness has becomemore prevalent since the 1950s biological
revolution in psychiatry, and thatmodern psychiatric drugs
are to blame.25
Specifically, he argues that our current psychiatricmedi-
cations are actually causing patients to developmore severe
and chronic forms of mental illness. Furthermore, he main-
tains that this is the case for virtually all illnesses, from
mood disorders and anxiety to schizophrenia. He grants30
that some medications may help patients initially (while
maintaining that others are no better than placebo in the
short run). However, it is not the initial therapeutic effects,
or lack thereof, that principally concern him. It is the long–
termeffects of these drugs.His thesis is that our brains are ir-35
reversibly changed by psychiatric medications in ways that
turn episodic and potentially manageable disorders into
chronic and severe disabilities.
The idea sounds wildly implausible. The drugs are not
just ineffective, but damaging? Irreparably so? Not just one40
class of drugs, but most of them? And the experts failed to
notice these facts? But let’s set aside the question of whether
it’s true for a moment, and agree on this much: If his hy-
pothesis were true, then it would be a matter of extraordi-
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nary public health importance. If the hypothesis were even 45
somewhat plausible, given Whitaker’s evidence, then it’s
an urgent and immensely important neuroethical issue, one
that we should take seriously and get busy investigating
further.
So how persuasive is Whitaker’s evidence? No single 50
book, let alone a book written by a journalist for laymen, is
going to settle an issue as enormous as this one. This issue, in
particular, comeswith built–in challenges. Researchprojects
using randomized experimental assignment to drug versus
placebo do not follow patients over periods of years, so 55
we lack the most decisive kind of evidence on the question
of long–term iatrogenic effects. In the absence of experi-
mental evidence, Whitaker turns to a variety of sources of
observational evidence, examining the correlation between
treatments administered to patients and their long–term 60
outcomes. Of course, sicker patients are more likely to be
medicated in the first place, a confound that would lead us
to expect worse outcomes after medication even if medica-
tion does not cause the worse outcomes. To a certain extent
such confounds can be corrected for statistically, but this is 65
never foolproof and in most cases was not even attempted.
Whitaker also takes a quasi–experimental approach, com-
paring patient outcomes across decades (before and after
the biological revolution in psychiatry) or countries (which
vary in their use of psychiatric medications). These com- 70
parisons offer a clever way to approximate the design of a
long–term experimental study, but they have confounds of
their own because of differences in the broader social and
medical contexts of patient care at different times and in
different societies. 75
I wish that Whitaker acknowledged the limitations of
the studies he cites more explicitly. Although he does note
the problems just mentioned at various points in the book,
he also loses sight of them at times. Take this footnote, for
example: “The caveat with the naturalistic studies is that 80
the unmedicated cohort, at the moment of initial diagnosis,
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may not be as depressed as those who go on the drugs. Fur-
thermore, those who eschew drugs may also have greater
“inner resilience.” Even given these caveats, we should be
able to gain a sense of the course of unmedicated depression85
from the naturalistic studies, and see how it compares to the
course of depression treated with antidepressants (p. 164).
But if we don’t know whether the medicated and unmedi-
cated cohorts differed from the beginning, then how canwe
use a comparison of their long–term outcomes to gain any90
sense of anything?
The dearth of strong evidence available on the long–
term effects of psychiatric medications, and Whitaker’s oc-
casional lapses of objectivity in data interpretation, make it
impossible to draw firm conclusions. Of course, where new95
hypotheses concerning public health are concerned, firm
conclusions are invariably more of a goal than a reality. I
believe Whitaker has succeeded in proposing a hypothesis
of potentially great importance and providing at least some
degree of support for it. At a minimum, he has highlighted100
how little we know about the long–term effects of treatment
with psychiatric medications. This in itself is an important
point.
I would have preferred fewer patient vignettes, but un-
derstand that a trade book needs to place the facts and 105
figures of epidemiology and clinical trials into a human
context. I also would have preferred less criticism of the
psychiatry establishment and the pharmaceutical industry,
not out of concern for either, but because it turns off somany
of the people who should be reading this book. 110
Overall, I found Whitaker’s book extremely thought-
provoking. His case is based on circumstantial evidence,
because this is the only kind of evidence we have. He
shows that a large amount of such evidence is consistent
with the long–term exacerbation of mental illness by psy- 115
chiatric medications. It is a “connecting-the-dots” kind of
argument, and could of course be mistaken. And this raises
the questions:
Is Whitaker mistaken?
How would we know? 120
And, in a societywhere substantial fractions of the adult
and child population are using psychiatric medications,
why do we not have better evidence concerning long–term
effects?
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